Get Your Personalized Supplement StackSupplement Stack Quiz

Hen of the Woods Mushroom

Also known as: Grifola frondosa, Hen of the Woods, Maitake, Sheep’s Head, Ram’s Head, Kumotake

Overview

Grifola frondosa, commonly known as Hen of the Woods or Maitake, is an edible mushroom native to Asia, Europe, and North America. It grows at the base of hardwood trees and is recognized for its potential health benefits, primarily attributed to its bioactive polysaccharides, especially β-glucans. As a dietary supplement, it is used for immune support, potential anticancer effects, and metabolic health. Research on Grifola frondosa is still in its early stages, with preclinical and early clinical studies suggesting promising results. While systematic reviews and meta-analyses are available for animal models, high-quality human randomized controlled trials (RCTs) with adequate sample sizes and controls are limited. The available evidence suggests moderate support from animal studies and low support from human RCTs, highlighting the need for further rigorous research to confirm its efficacy and safety in humans. It is available in various forms, including dried mushroom, extracts, and supplements.

Benefits

Grifola frondosa exhibits several potential health benefits, primarily supported by preclinical and early clinical research. Animal studies and meta-analyses suggest antitumor activity, with high-dose Grifola frondosa polysaccharide (GFP) significantly inhibiting tumor growth in animal models. Additionally, purified GFP has demonstrated anti-inflammatory effects by reducing colonic shortening and pro-inflammatory cytokines in animal models of colitis. Some animal studies also indicate improved glucose tolerance and cholesterol reduction, suggesting potential metabolic health benefits, although human data are limited. These findings suggest that Grifola frondosa may have potential adjunctive use in cancer therapy and inflammatory bowel disease, but more robust human trials are needed to confirm these effects. The effect size for tumor inhibition in animal models is clinically meaningful for preclinical research, but its translation to human clinical outcomes remains uncertain.

How it works

Grifola frondosa's mechanism of action primarily involves immunomodulation through the activation of macrophages, natural killer cells, and dendritic cells via β-glucan receptors. These receptors recognize β-glucans, triggering immune responses that enhance both innate and adaptive immunity. In terms of antitumor effects, Grifola frondosa operates through host-mediated mechanisms, including enhanced immune surveillance and the induction of apoptosis in cancer cells. Additionally, it exhibits anti-inflammatory effects by reducing pro-inflammatory cytokines such as TNF-α and IL-6, while increasing anti-inflammatory factors. The mushroom's interaction with the body systems includes enhancing the immune system and potentially improving glucose and lipid metabolism in the metabolic system. Molecularly, it targets the Dectin-1 receptor, which recognizes β-glucans, initiating immune responses. The polysaccharides in Grifola frondosa are poorly absorbed orally, suggesting that its effects are likely mediated via gut-associated lymphoid tissue and systemic immune modulation.

Side effects

Grifola frondosa is generally considered safe when consumed as food, with limited adverse events reported in supplement studies. Common side effects are rarely reported, but mild gastrointestinal discomfort is possible. Uncommon side effects are not well-documented in controlled studies. Rare side effects include possible allergic reactions, although these are infrequent. No significant drug interactions have been reported, but there is a theoretical risk with immunosuppressants due to its immunomodulatory effects. There are no established contraindications, but caution is advised for immunocompromised individuals. The safety of Grifola frondosa in pregnancy, lactation, and children has not been established, warranting caution in these populations. Long-term safety data are lacking, and individuals should discontinue use if allergic symptoms occur. While generally safe, it is important to monitor for any adverse reactions and consult with a healthcare provider, especially for those with pre-existing conditions or those taking other medications.

Dosage

The minimum effective dose of Grifola frondosa is not well-established in humans, with animal studies using doses equivalent to several grams of mushroom extract per day. Human studies often use 3–7 grams of dried mushroom or equivalent extract daily, but the optimal dose for specific effects remains unclear. The maximum safe dose has not been established, but no toxicity has been reported at typical supplement doses. There are no specific timing recommendations, but it may be taken with meals to reduce gastrointestinal discomfort. Standardized extracts, such as D-fraction, are preferred for consistent polysaccharide content. Polysaccharides are poorly absorbed, suggesting that effects are likely local (gut) and systemic (immune). No required cofactors have been identified. Further research is needed to determine precise dosing guidelines and long-term safety thresholds.

FAQs

Is Grifola frondosa effective in humans?

Most evidence is from animal models; human data are limited and of lower quality. More robust human trials are needed to confirm its efficacy.

Is Grifola frondosa safe?

Generally safe, but long-term safety data are lacking. Discontinue if allergic symptoms occur or if you are taking immunosuppressants.

How should I take Grifola frondosa?

May be taken daily, with or without food. Follow dosage recommendations on the product label or as advised by a healthcare provider.

What results can I expect from taking Grifola frondosa?

Possible modest immune enhancement based on preclinical data. There is no robust evidence for efficacy in humans for cancer support.

Can Grifola frondosa cure cancer?

Not supported by current evidence; may have adjunctive benefits. Benefits, if any, are likely gradual and subtle.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/34271115/ – This meta-analysis of animal studies found that high-dose Grifola frondosa polysaccharide (GFP) significantly inhibited tumor growth. The study followed PRISMA and SYRCLE guidelines, indicating a moderate quality assessment, but the findings are limited to animal models and may not directly translate to human outcomes.
https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1078868/full – This preclinical study demonstrated that purified GFP (92.5% purity) reduced colonic shortening and pro-inflammatory cytokines in an animal model of colitis. The well-controlled extraction and analysis contribute to the moderate quality assessment, but the absence of human data limits the applicability of these findings to human health.
https://www.liebertpub.com/doi/full/10.1089/acm.2009.0696?src=recsys – This research explores the metabolic effects of Grifola frondosa, noting improvements in glucose tolerance and cholesterol reduction in animal models. The human data are limited and not from large, well-controlled RCTs, resulting in a low quality assessment for human evidence, while the animal studies are considered of moderate quality.
https://www.e-jarb.org/journal/view.html?doi=10.12750%2FJARB.36.4.203 – This study investigates the effects of Grifola frondosa, providing additional support for its potential metabolic benefits. While the specific details of the study are not fully elaborated in the provided summary, it contributes to the overall body of evidence suggesting positive metabolic outcomes, primarily in animal models.